Skip to main content
Top
Published in: Supportive Care in Cancer 3/2018

Open Access 01-03-2018 | Original Article

How do treatment aims in the last phase of life relate to hospitalizations and hospital mortality? A mortality follow-back study of Dutch patients with five types of cancer

Authors: Mariska Oosterveld-Vlug, Gé Donker, Femke Atsma, Linda Brom, Yvonne de Man, Stef Groenewoud, Bregje Onwuteaka-Philipsen

Published in: Supportive Care in Cancer | Issue 3/2018

Login to get access

Abstract

Purpose

The purpose of this study is to describe and compare the relation between treatment aims, hospitalizations, and hospital mortality for Dutch patients who died from lung, colorectal, breast, prostate, or pancreatic cancer.

Methods

A mortality follow-back study was conducted within a sentinel network of Dutch general practitioners (GPs), who recorded the end-of-life care of 691 patients who died from one of the abovementioned cancer types between 2009 and 2015. Differences in care by type of cancer were analyzed using multilevel analyses to control for clustering within general practices.

Results

Among all cancer types, patients with prostate cancer most often and patients with pancreatic cancer least often had a palliative treatment aim a month before death (95% resp. 84%). Prostate cancer patients were also least often admitted to hospital in the last month of life (18.5%) and least often died there (3.1%), whereas lung cancer patients were at the other end of the spectrum with 41.8% of them being admitted to hospital and 22.6% dying in hospital. Having a palliative treatment aim and being older were significantly associated with less hospital admissions, and having a palliative treatment aim, having prostate cancer, and dying in a more recent year were significantly associated with less hospital deaths.

Conclusion

There is large variation between patients with different cancer types with regard to treatment aims, hospital admissions, and hospital deaths. The results highlight the need for early initiation of GP palliative care to support patients from all cancer types to stay at the place they prefer as long as possible.
Appendix
Available only for authorised users
Literature
3.
10.
go back to reference McKinley RK, Stokes T, Exley C, Field D (2004) Care of people dying with malignant and cardiorespiratory disease in general practice. Br J Gen Pract 54:909–913PubMedPubMedCentral McKinley RK, Stokes T, Exley C, Field D (2004) Care of people dying with malignant and cardiorespiratory disease in general practice. Br J Gen Pract 54:909–913PubMedPubMedCentral
19.
go back to reference Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM (2003) Patterns of functional decline at the end of life. JAMA 289:2387–2392CrossRefPubMed Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM (2003) Patterns of functional decline at the end of life. JAMA 289:2387–2392CrossRefPubMed
28.
go back to reference Statistics Netherlands (2014) CBS statline Ziekenhuisopnamen; geslacht, leeftijd en diagnose-indeling. [Hospital admissions; gender, age and diagnosis]. Via http://bit.ly/2lZLJnH. Accessed 2-3-2017 Statistics Netherlands (2014) CBS statline Ziekenhuisopnamen; geslacht, leeftijd en diagnose-indeling. [Hospital admissions; gender, age and diagnosis]. Via http://​bit.​ly/​2lZLJnH. Accessed 2-3-2017
29.
go back to reference Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ (2016) Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA 315:272–283. https://doi.org/10.1001/jama.2015.18603 CrossRefPubMed Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ (2016) Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA 315:272–283. https://​doi.​org/​10.​1001/​jama.​2015.​18603 CrossRefPubMed
34.
36.
go back to reference Cohen J, Pivodic L, Miccinesi G, Onwuteaka-Philipsen BD, Naylor WA, Wilson DM, Loucka M, Csikos A, Pardon K, Van den Block L, Ruiz-Ramos M, Cardenas-Turanzas M, Rhee Y, Aubry R, Hunt K, Teno J, Houttekier D, Deliens L (2015) International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data. Br J Cancer 113:1397–1404. https://doi.org/10.1038/bjc.2015.312 CrossRefPubMedPubMedCentral Cohen J, Pivodic L, Miccinesi G, Onwuteaka-Philipsen BD, Naylor WA, Wilson DM, Loucka M, Csikos A, Pardon K, Van den Block L, Ruiz-Ramos M, Cardenas-Turanzas M, Rhee Y, Aubry R, Hunt K, Teno J, Houttekier D, Deliens L (2015) International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data. Br J Cancer 113:1397–1404. https://​doi.​org/​10.​1038/​bjc.​2015.​312 CrossRefPubMedPubMedCentral
37.
go back to reference Ploemacher J, Israëls AZ, Van der Laan DJ, De Bruin A (2013) Gestandaardiseerde ziekenhuissterfte daalt in de tijd [Standardised in-hospital mortality decreasing over time]. Ned Tijdschr Geneeskd 157:A5267PubMed Ploemacher J, Israëls AZ, Van der Laan DJ, De Bruin A (2013) Gestandaardiseerde ziekenhuissterfte daalt in de tijd [Standardised in-hospital mortality decreasing over time]. Ned Tijdschr Geneeskd 157:A5267PubMed
Metadata
Title
How do treatment aims in the last phase of life relate to hospitalizations and hospital mortality? A mortality follow-back study of Dutch patients with five types of cancer
Authors
Mariska Oosterveld-Vlug
Gé Donker
Femke Atsma
Linda Brom
Yvonne de Man
Stef Groenewoud
Bregje Onwuteaka-Philipsen
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 3/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3889-z

Other articles of this Issue 3/2018

Supportive Care in Cancer 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine